Konakion Mm (Phytomenadione)

• Konakion Mm, a vitamin K agent, is used to manage disorders of coagulation by supplying the essential cofactor for clotting factor activation.
• Vitamin K deficiency: restores normal clotting factor activity in patients with insufficient vitamin K levels, reducing bleeding risk.
• Prevention of hemorrhage in newborns: administered shortly after birth to newborns to prevent vitamin K‑deficiency bleeding.
• Reversal of anticoagulant (warfarin) over‑dosage: provides rapid replenishment of vitamin K to counteract excessive anticoagulation and normalize INR.

• Phytomenadione acts as a cofactor for the enzyme γ‑glutamyl carboxylase, enabling the γ‑carboxylation of glutamate residues on clotting factors II, VII, IX and X as well as proteins C and S. This post‑translational modification is required for calcium binding and functional activity of the factors, thereby restoring normal coagulation pathways.

Phytomenadione may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects

• Injection site pain or erythema
• Mild fever
• Nausea or vomiting
• Headache or dizziness

Serious or Rare Side Effects

• Anaphylactic or severe allergic reaction
• Thrombosis or embolic events
• Hemolytic anemia

• Before using Konakion Mm, several precautionary measures should be considered to ensure safe administration.
• Assess bleeding risk: evaluate patient’s coagulation status and recent anticoagulant use.
• Monitor for hypersensitivity: observe for signs of allergic reaction during and after administration.
• Use with caution in liver disease: impaired synthesis of clotting factors may alter response.
• Avoid in newborns with contraindications: follow neonatal dosing guidelines.
• Store at below 25°C: keep in the original pack, protect from moisture.

Phytomenadione can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Warfarin and other vitamin K antagonists: may diminish anticoagulant effect and increase clotting risk.
• High‑dose vitamin K supplements: may counteract therapeutic action of Konakion Mm.

Moderate Interactions (Monitor Closely)

• Broad‑spectrum antibiotics (e.g., cephalosporins): may alter gut flora and affect vitamin K levels, requiring monitoring.
• Lipid‑lowering agents such as cholestyramine: can bind vitamin K and reduce its absorption.
• Oral contraceptives: may increase vitamin K activity, necessitating periodic coagulation assessment.